PT - JOURNAL ARTICLE AU - Kogler, Valery J. AU - Miles, Jeffrey A. AU - Özpolat, Tahsin AU - Bailey, S. Lawrence AU - Byrne, Daire A. AU - Bawcom-Randall, Morgan AU - Wang, Yi AU - Larsen, Hannah J. AU - Reed, Franklin AU - Fu, Xiaoyun AU - Stolla, Moritz TI - Platelet dysfunction reversal with cold-stored vs. room temperature-stored platelet transfusions AID - 10.1101/2023.09.17.23295666 DP - 2023 Jan 01 TA - medRxiv PG - 2023.09.17.23295666 4099 - http://medrxiv.org/content/early/2023/09/17/2023.09.17.23295666.short 4100 - http://medrxiv.org/content/early/2023/09/17/2023.09.17.23295666.full AB - Background Platelets are stored at room temperature for 5-7 days (RSP). Due to frequent and severe shortages, the FDA recently approved up to 14-day cold-stored platelets in plasma (CSP). However, the post-transfusion function of CSP is unknown and it is unclear which donors are best suited to provide either RSP and/or CSP.Objective To evaluate the post-transfusion function and predictors of post-transfusion function for platelets stored for the maximum approved storage times (7-day RSP, 14-day CSP) in healthy volunteers on acetylsalicylic acid (ASA).Methods We conducted a randomized cross-over study in ten healthy humans. Subjects donated one platelet unit stored at either RT (RSP) or 4 °C (CSP) based on randomization. Before transfusion, subjects ingested ASA to inhibit endogenous platelets. Transfusion recipients were tested for platelet function and lipid mediators. Platelet units were tested for lipid mediators only. A second round with transfusion of the alternative product and an identical testing sequence followed.Results RSP reversed platelet inhibition significantly better in αIIbβ3 integrin activation-dependent assays. In contrast, CSP led to significantly more thrombin generation in recipients, which was not dependent on platelet microparticles, but CSP themselves. Lysophosphatidylcholine-O (Lyso-Platelet Activating Factor) species levels predicted the procoagulant capacity of CSP. In contrast, polyunsaturated fatty acid concentration predicted the aggregation response of RSP.Conclusion We provide the first efficacy data of extended-stored CSP in plasma. Our results suggest that identifying ideal RSP and CSP donors is possible and pave the way for larger studies in the future. Graphical Abstract 1: Overview of CSP function after 14 days of storage (Created with Biorender)Competing Interest StatementM.S. received research funding from Cerus Corp. and Terumo BCT.Clinical TrialNCT03787927Funding StatementThis study was funded by the Department of DefenseAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:WCG-IRB (formerly Western-IRB) gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors